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        Allograft blood vessels are major targets of clin-
ical rejection responses (  1, 2  ). Acute vascular 
rejection may be mediated either by alloreac-
tive T cells, producing a lesion called intimal 
arteritis, or by alloreactive antibodies (  3, 4  ). 
Chronic vascular rejection, characterized by 
concentric intimal expansion and inadequate 
compensatory outward remodeling, resulting 
in luminal stenosis, is a major cause of late graft 
failure (  1  ). Both of these forms of vascular re-
jection are particularly resistant to current ther-
apies, and increased understanding of their 
pathogenesis may suggest new therapies. 
  Graft endothelial cells (ECs) appear to be a 
likely target of the host immune response against 
graft vasculature (  5  ). Human ECs can directly 
activate allogeneic memory T cells, and eff  ector 
memory T cells can directly injure the microves-
sels of allogeneic human skin (  5, 6  ). Alloreactive 
memory T cells, which comprise roughly half of 
the total circulating alloreactive T cells in hu-
mans (  7, 8  ), diff  er in their activation require-
ments and susceptibility to immunosuppression 
from naive T cells, and have been suggested to 
pose a signifi   cant barrier to the induction of 
transplant tolerance in humans (  9  ). This compo-
nent of the host antigraft immune response is 
frequently overlooked in transplant models using 
rodents, which typically lack signifi  cant numbers 
of circulating memory T cells. 
  Allograft endothelial injury is often initi-
ated by perioperative ischemia-reperfusion in-
jury, which predisposes allografts to both acute 
and chronic rejection (  10, 11  ). We have hy-
pothesized that such injury causes ECs to ex-
pose  “  alarmins  ”   that promote a more destructive 
antigraft immune response. In support of this 
hypothesis, we have previously shown that 
freeze  –  thaw  –  injured ECs release IL-1    , which 
enhances alloreactive T cell IFN-     and IL-17 
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  Interleukin (IL) 1     produced by human endothelial cells (ECs), in response to tumor necro-
sis factor (TNF) or to co-culture with allogeneic T cells in a TNF-dependent manner, can 
augment the release of cytokines from alloreactive memory T cells in vitro. In a human  –
  mouse chimeric model of artery allograft rejection, ECs lining the transplanted human 
arteries express IL-1    , and blocking IL-1 reduces the extent of human T cell infi  ltration 
into the artery intima and selectively inhibits IL-17 production by infi  ltrating T cells. In 
human skin grafts implanted on immunodefi  cient mice, administration of IL-17 is suffi  cient 
to induce mild infl  ammation. In cultured cells, IL-17 acts preferentially on vascular smooth 
muscle cells rather than ECs to enhance production of proinfl  ammatory mediators, includ-
ing IL-6, CXCL8, and CCL20. Neutralization of IL-17 does not reduce T cell infi  ltration into 
allogeneic human artery grafts, but markedly reduces IL-6, CXCL8, and CCL20 expression 
and selectively inhibits CCR6  +   T cell accumulation in rejecting arteries. We conclude that 
graft-derived IL-1 can promote T cell intimal recruitment and IL-17 production during 
human artery allograft rejection, and suggest that targeting IL-1 in the perioperative 
transplant period may modulate host alloreactivity. 
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    RESULTS   
  IL-1     expression in human vascular cells 
  Because IL-1 can modulate human alloreactive T cell re-
sponses in vitro (  12  ), we examined expression of IL-1     by 
the two principle cell types of the vessel wall, ECs and SMCs. 
Both ECs and SMCs typically express low levels of IL-1     in 
culture; however, IL-1     expression in both cell types could 
be markedly up-regulated by treatment with TNF (  Fig. 1 A  ).   
TNF treatment increased the amount of IL-1     contained in 
EC or SMC lysates without causing accumulation of IL-1     
in the culture media, consistent with previous observations 
that TNF-induced IL-1     remains cell associated in ECs (  36  ). 
EC but not SMC expression of IL-1     was also increased after 
co-culture with allogeneic CD4  +   T cells. In these experi-
ments, EC MHC class II expression lost during culture was 
restored by retroviral transduction with class II transactivator 
(  Fig. 1 B  ) or pretreatment with IFN-     (Fig. S1, available at 
http://www.jem.org/cgi/content/full/jem.20081661/DC1) 
before co-culture. The increase in EC IL-1     expression in-
duced by co-culture with alloreactive T cells could be inhib-
ited by addition of a neutralizing antibody to TNF (  Fig. 1 C  ), 
suggesting that allogeneic T cells enhance IL-1     expression in 
ECs by secreting TNF. In contrast, IL-1     expression in MHC 
class II  –  positive SMCs was not changed after co-culture with 
allogeneic CD4  +   T cells (Fig. S1), consistent with the ability 
of ECs but not SMCs to induce cytokine production from 
resting allogeneic T cells (  37  ). 
  EC-expressed IL-1     skews alloreactive CD4  +   T cells 
toward IL-17 production 
  To examine eff  ects of EC-expressed IL-1     on the allogeneic 
response, we co-cultured purifi  ed  CD4  +   memory T cells 
with allogeneic MHC class II  –  positive ECs either pretreated 
with TNF or left untreated. Similar to eff  ects of exogenous 
IL-1 (  12  ), ECs pretreated with TNF stimulated increased 
production of IFN-     and IL-17 from allogeneic memory 
CD4  +   T cells compared with untreated ECs (  Fig. 1 D  ). Most 
of this enhanced immunogenicity was blocked by addition of 
a neutralizing antibody to IL-1    . 
  To determine whether EC-expressed IL-1     can polarize 
alloreactive memory CD4  +   T cell responses, we performed 
restimulation assays in which CD4  +   memory T cells were 
co-cultured with either TNF-pretreated or untreated alloge-
neic ECs for 3 d, rested, and then restimulated by co-culture 
with fresh, untreated ECs from the same donor as the pri-
mary culture. CD4  +   T cells that were co-cultured with 
TNF-pretreated ECs during the primary stimulation selec-
tively produced more IL-17 upon restimulation than did T 
cells initially co-cultured with untreated ECs, with no sig-
nifi  cant change in IFN-     or IL-5 production (  Fig. 1 E  ). 
Neutralization of IL-1     during the primary co-culture com-
pletely blocked the ability of TNF-treated ECs to skew the 
alloreactive population toward IL-17 production. 
  To confi  rm that EC-expressed IL-1     alters the number 
of T cells that produce IL-17 upon restimulation, T cell cy-
tokine production was also analyzed by intracellular cytokine 
production in EC  –  T cell co-cultures (  12  ). IL-1     and the re-
lated cytokine IL-1     are prototypical proinfl  ammatory cyto-
kines that elicit essentially indistinguishable responses through 
IL-1R1; however, unlike IL-1    , IL-1     stored intracellularly 
is both bioavailable and bioactive as a cytokine in its unpro-
cessed form (  13  ). 
  A pathological role for eff  ector T cell  –  derived IFN-     in 
vascular rejection is well supported experimentally (  14  ); how-
ever, the contribution of IL-17 to vascular rejection remains 
unclear. T cell production of IL-17 plays a critical role in sev-
eral mouse models of autoimmune disease, including experi-
mental autoimmune encephalomyelitis, arthritis, and colitis, 
and has also been implicated in acute rejection of mouse het-
erotopic heart transplants (  15  –  18  ). Elevated plasma or tissue 
levels of IL-17 have been reported in patients with autoim-
mune diseases, including multiple sclerosis, rheumatoid ar-
thritis, infl   ammatory bowel disease, and psoriasis (  19  –  22  ). 
Additionally, increased numbers of T cells capable of induc-
ing IL-17  –  dependent infl   ammation correlates with an in-
creased risk of obliterative bronchiolitis, a form of chronic 
rejection in lung transplants (  23  ). Although not completely 
specifi  c, IL-17  –  producing T cells, sometimes referred to as 
  “  infl  ammatory  ”   T helper cells (  24  ), can be generally identi-
fi  ed by expression of CCR6 (  25, 26  ). IL-17 induces expres-
sion of infl  ammatory molecules such as IL-6, CXCL8 (also 
known as IL-8), and CCL20, the only known CCR6 ligand, 
in several human cell types in vitro (  27  ); however, specifi  c 
pathologic processes induced by IL-17 in intact human tissues 
have not yet been demonstrated. 
  The factors that promote T cell IL-17 production appear 
to diff  er between humans and mice. The combination of 
TGF-     and IL-6 is suffi   cient to induce Th17 diff  erentiation 
in mouse but not human naive T cells (  28  –  32  ). Although the 
eff  ect of TGF-     on human T cells remains controversial, sev-
eral groups have demonstrated a critical role for IL-1 in the 
diff  erentiation of naive human T cells toward an IL-17  –  pro-
ducing phenotype (  31, 33  –  35  ). IL-17 production is more 
easily induced in memory T cells than naive T cells, and IL-1 
enhances IL-17 production from alloreactive memory CD4  +   
T cells in human mixed lymphocyte  –  endothelial reactions 
(  12, 32  ). However, the relevance of these factors to human T 
cell cytokine production in vivo is unknown. 
  In this paper, we demonstrate that ECs expressing high 
levels of cell-associated IL-1    , like soluble IL-1, can selec-
tively skew alloreactive CD4  +   memory T cells toward produc-
tion of IL-17 in vitro. More signifi  cantly, in a human  –  mouse 
chimeric model of memory T cell  –  mediated allograft artery 
rejection, graft-derived IL-1 enhances allogeneic T cell infi  l-
tration into the vessel intima, causing intimal expansion, and 
specifi  cally promotes IL-17 production from infi  ltrating hu-
man T cells. IL-17, in turn, drives an infl  ammatory cascade 
that selectively promotes recruitment of CCR6  +   T cells into 
rejecting artery allografts, principally through its actions on 
smooth muscle cells (SMCs). These observations identify a 
central role for IL-1 in modulating human T cell responses to 
allograft vasculature. JEM VOL. 205, December 22, 2008 
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    Figure 1.         Human ECs use cell-associated IL-1         to promote alloreactive memory CD4  +   T cell IL-17 production.   (A) ECs or SMCs were treated 
with 10 ng/ml TNF for the indicated times, and cell lysates and supernatants were assayed for IL-1     by ELISA. (B) MHC class II  –  positive ECs were co-cul-
tured with allogeneic CD4  +   T cells for the indicated times, and then ECs were purifi  ed and assayed for IL-1     in EC lysates and supernatants by ELISA. For A 
and B, data from one of three experiments with similar results are shown. (C) MHC class II  –  positive ECs were co-cultured with CD4  +   T cells for 48 h with a 
neutralizing anti-TNF antibody or isotype control, and IL-1     in  purifi  ed EC lysates was measured by ELISA. Means   ±   SEM (  n   = 3 experiments) are shown. 
(D) Untreated or TNF-pretreated ECs were co-cultured with allogeneic memory CD4  +   T cells with 5   μ  g/ml of a neutralizing anti  –  IL-1     antibody or isotype 
control. Culture medium was assayed for IFN-     and IL-17 by ELISA at 24 h. (E) CD4  +   T cells from primary co-cultures were restimulated with fresh ECs, 
and the culture medium was assayed for IFN-    , IL-17, and IL-5 by ELISA at 24 h. Means   ±   SEM of fold changes relative to the untreated, isotype control 
group from seven (D) or three (E) experiments are shown. The ranges of values in the control group were 1  –  33 pg/ml (IFN-    ) and 1  –  10 pg/ml (IL-17) in D, 
and 301  –  645 pg/ml (IFN-    ), 5  –  128 pg/ml (IL-17), and 8  –  428 pg/ml (IL-5) in E. (F) Purifi  ed memory CD4  +   T cells were co-cultured with CD32-transduced, 
anti-CD3 mAb  –  coated ECs that were either pretreated with TNF or left untreated, and then T cells were restimulated with PMA plus ionomycin and ana-
lyzed by ICS. A neutralizing antibody to IL-1     or isotype control was added to the primary co-culture as indicated. Means   ±   SEM of fold changes relative 
to the untreated, isotype control group from six different donors are shown. (G) CFSE-labeled memory CD4  +   T cells co-cultured with allogeneic ECs for 
14 d were restimulated with PMA and ionomycin and analyzed by ICS. Representative dot plots of CFSE dilution and IL-17 expression in CD45  + -gated 
lymphocytes are shown (numbers indicate percentages). (H) Scatter plot of the fraction of CFSE-low, IL-17  +   cells in individual microtiter co-cultures. 
Pooled data from two experiments with similar results are shown. Horizontal bars indicate means. *, P   <   0.05; #, P   <   0.01;    ,  P   <   0.001.   3148 IL-1 IN HUMAN EXPERIMENTAL ALLOGRAFT REJECTION   | Rao et al. 
planted into immunodefi  cient SCID/beige mice as infrarenal 
aortic interposition grafts, and allogeneic human PBMCs are 
then adoptively transferred. Adoptive transfer of human PBMCs 
into SCID/beige mice yields stable engraftment of circulat-
ing populations of human CD3  +   T cells capable of mediating 
graft rejection but does not result in engraftment of human 
monocytes, macrophages, DCs, neutrophils, or natural killer 
cells (  39  ). 
  Expression of IL-1     was consistently detected in the en-
dothelium of human artery interposition grafts, as well as in 
occasional cells in the media and adventitia (  Fig. 2 A  ).   To test 
whether IL-1 modulates human T cell responses to alloge-
neic artery grafts in vivo, allogeneic PBMCs were adoptively 
transferred into mice recently grafted with human artery, and 
the mice were treated with IL-1R antagonist (IL-1Ra) or 
PBS daily for 21 d. In sequential experiments, two doses of 
IL-1Ra were used (50 and 150 mg/kg/day) that yielded sim-
ilar eff  ects; therefore, data from the two doses were pooled 
staining (ICS). Because the frequency of human CD4  +   T 
cells that can be activated by allogeneic ECs is low, detection 
of cytokine-positive T cells by ICS after co-culture with al-
logeneic ECs is diffi   cult. Therefore, we used a model, devel-
oped in our laboratory, in which ECs are transduced to 
express the Fc    R CD32 and overlayed with anti-CD3 mAb 
(  38  ). T cells co-cultured with these ECs are activated poly-
clonally by a defi  ned TCR signal in the context of the co-
stimulatory molecules expressed by human ECs. Purifi  ed 
memory CD4  +   T cells were co-cultured with CD32-trans-
duced, anti-CD3 mAb  –  coated ECs that had been either pre-
treated with TNF to induce IL-1     or left untreated, and an 
anti  –  IL-1     antibody or an isotype control was added. After 
3 d of primary co-culture, T cells were rested for 3 d and 
then restimulated with PMA plus ionomycin and evaluated 
by ICS. Consistent with the results generated by ELISA, 
neutralization of IL-1     during the primary co-culture of 
TNF-treated ECs and CD4  +   T cells signifi  cantly reduced 
the number of T cells that produced IL-17 upon restimula-
tion (  Fig. 1 F  ) but had no eff  ect on the number of IFN-      –
  producing T cells. In this system, neutralization of IL-1     
appeared to slightly reduce the number of IL-17  –  producing 
cells in co-cultures in which the ECs were not pretreated 
with TNF before co-culture, most likely because the large 
number of activated T cells produce enough TNF during 
the primary culture to rapidly enhance IL-1     expression by 
the ECs. IL-1     neutralization also modestly reduced the 
number of IL-4  –  producing T cells, although we did not ob-
serve a similar pattern when measuring IL-5 production in 
allogeneic restimulation assays by ELISA. 
  In addition, we asked whether IL-1     produced by ECs in 
response to alloreactive T cells might in turn alter IL-17 pro-
duction by the alloreactive T cell population. To examine 
this, CFSE-labeled memory CD4  +   T cells were co-cultured 
with allogeneic ECs in replicate microtiter wells with or 
without addition of an anti  –  IL-1     neutralizing antibody for 
14 d and were then restimulated with PMA and ionomycin. 
Alloreactive T cells were identifi  ed as cells that had prolifer-
ated and diluted the CFSE dye, and the number of alloreac-
tive cells expressing IL-17 in each well was quantifi  ed by 
ICS. Neutralization of IL-1     in these co-cultures did not af-
fect total alloreactive T cell proliferation (unpublished data) 
but signifi  cantly reduced the number of alloreactive T cells 
that produced IL-17 upon restimulation (  Fig. 1, G and H  ). 
Collectively, these results indicate that IL-1     expressed by 
human ECs, as previously shown for recombinant IL-1 (  12  ), 
enhances early IFN-     and IL-17 production from alloreac-
tive CD4  +   T cells and further directs alloreactive CD4  +   
memory T cells selectively toward production of IL-17. 
  Vascular cell  –  expressed IL-1 promotes T cell intimal 
infi  ltration and IL-17 production in vivo 
  We next examined the eff  ect of IL-1 in directing human T 
cell responses to allogeneic human artery grafts in vivo using 
a human  –  mouse chimeric model of intimal arteritis. In this 
model, short segments of human coronary artery are im-
    Figure 2.         IL-1 blockade reduces T cell  –  mediated injury and IL-17 
production in human artery allografts.   (A) Immunohistochemical de-
tection of human endothelium (CD31) and IL-1     in a human artery aortic 
interposition graft. Staining with an isotype-matched primary antibody is 
shown as a control. Bars, 25   μ  m. (B) 5-  μ  m transverse sections were 
stained with EVG, and the total vessel area (area bounded by the external 
elastic lamina and the lumen) and the intimal area (area bounded by the 
internal elastic lamina and the lumen) were quantifi  ed using ImageJ soft-
ware. Bars, 100   μ  m. (C) Immunohistochemical identifi  cation and quantifi  -
cation of human CD45RO  +   T cells in graft intimas. Bars, 25   μ  m. (D) RT-PCR 
analysis of CD3     (normalized to GAPDH), IFN-    , and IL-17 (normalized to 
CD3    ), and the ratio of IL-17/IFN-     in artery grafts undergoing T cell  –
 mediated  rejection.  For  B – D,  means   ±   SEM  ( n   = 10 per group) are shown. 
*,  P   <   0.05.   JEM VOL. 205, December 22, 2008 
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fused primarily through human microvessels, which anasto-
mose with mouse vessels at the edges of the graft (  39  ). Grafts 
injected with IL-17 showed a modest degree of infi  ltration 
with mouse neutrophils, as well as increased expression of 
IL-6 and CCL20 (  Fig. 4, A and B  ).   We also observed variable 
increases in CXCL1 and CXCL8 that did not reach statistical 
signifi  cance (unpublished data). In addition, occasional hu-
man E-selectin  –  positive vessels could be found in IL-17  –  in-
jected grafts (  Fig. 4 C  ). Thus, administration of IL-17 alone 
induces mild infl  ammation in an intact human tissue. 
  To investigate which cells within an artery wall respond 
to IL-17 secreted by infi  ltrating T cells, we tested the ability 
of IL-17 to induce infl  ammatory responses in cultured human 
vascular cells. Treatment of cultured ECs with IL-17 slightly 
increased transcript expression of IL-6, CXCL8, and CCL20 
but did not alter protein secretion of these mediators or induce 
adhesion molecule expression (  Fig. 5, A  –  C  ).   The positive ef-
fect of TNF on E-selectin and intercellular adhesion molecule 
(ICAM) 1 protein in replicate cultures is clear cut (  Fig. 5 C  ). 
The lack of adhesion molecule induction on cultured ECs 
by IL-17 suggests that the E-selectin expression observed 
on some vessels in IL-17  –  treated skin may be induced indi-
rectly. In contrast to the limited EC response, SMCs treated 
with IL-17 increased transcript levels of IL-6, CXCL8, and 
CCL20 in a time- and dose-dependent manner and markedly 
increased secretion of these proteins (  Fig. 5, D  –  F  ). The ability 
of IL-17 to induce CCL20 secretion in SMCs was relatively 
minor compared with that of TNF; however, IL-17 syner-
gized with TNF to yield markedly elevated CCL20 secretion 
(  Fig. 5 G  ). Microarray analyses of IL-17  –  treated SMCs identi-
fi  ed additional cytokines and chemokines induced by IL-17, 
several of which were confi  rmed by RT-PCR (  Table I   and 
Table S1, available at http://www.jem.org/cgi/content/full/
jem.20081661/DC1).   Induction of most of these genes could 
not be prevented by cycloheximide, indicating that these 
genes are directly induced by IL-17 without the requirement 
for new protein synthesis. 
  T cell  –  derived IL-17 promotes infl  ammation and CCR6  +   
T cell accumulation in vivo 
  We next investigated the role of IL-17 in this model of hu-
man artery allograft rejection. Human allogeneic PBMCs 
were again adoptively transferred into mice transplanted with 
human artery interposition grafts, and the mice were treated 
with a neutralizing antibody to IL-17 or an isotype-matched 
control antibody for 4 wk. Neutralization of IL-17 did not 
reduce intimal expansion and had no eff  ect on total T cell in-
fi  ltration into human artery grafts, as assessed by RNA and 
immunohistochemistry (  Fig. 6, A and B  ).   IL-17 neutraliza-
tion also did not signifi  cantly alter IFN-     or IL-17 expression 
within the grafts (  Fig. 6 C  ). However, inhibition of IL-17 
markedly diminished graft expression of IL-6, CXCL8, and 
CCL20, three genes that may participate in a potential in-
fl   ammatory Th17 cytokine axis, but not expression of 
CXCL10, an IFN-      –  inducible chemokine (  Fig. 6 C  ). The 
decrease in CCL20 expression appears to have functional 
to generate larger numbers for analysis. Treatment with IL-
1Ra did not alter the number of circulating human T cells 
after PBMC transfer (Fig. S2, available at http://www.jem
.org/cgi/content/full/jem.20081661/DC1); however, IL-1 
blockade signifi  cantly reduced the total vessel area, the inti-
mal area, and the number of intimal T cells in rejecting artery 
grafts (  Fig. 2, B and C  ). 
  We also examined expression of T cell eff  ector cytokines 
within the rejecting artery grafts. Blockade of IL-1 signifi  -
cantly decreased the expression of IL-17 in treated grafts 
when normalized either to the T cell marker CD3     or to 
GAPDH (  Fig. 2 D  ; and not depicted). In the same speci-
mens, IL-1 blockade caused a corresponding increase in the 
amount of IFN-     per T cell in the grafts, yielding a signifi  -
cantly altered ratio of IL-17/IFN-     production from graft-
infi  ltrating T cells. 
  In mouse systems, IL-17 is principally produced by a 
CD4  +   eff  ector T cell subset that expresses retinoic acid  –  re-
lated orphan receptor (ROR)     T, designated as Th17 cells 
(  40, 41  ). In humans, IL-17  –  producing CD4  +   T cells express 
CD161, IL-23R, CCR6, and RORC (the human equivalent 
of ROR    T), but human cells expressing these markers may 
produce IL-17, IFN-    , or both cytokines (  25, 26, 42  ). Ex-
pression of these genes and of genes typically associated with 
classical Th1 cells, including CXCR3, IL-12R    2, and T-bet, 
could be detected in artery grafts infi  ltrated with allogeneic T 
cells but not in control grafts without T cells; however, no 
signifi  cant changes were observed in the expression of these 
genes per T cell as a result of IL-1 blockade (  Fig. 3 A  ).   Fur-
thermore, IL-1 neutralization did not signifi  cantly alter ex-
pression of any of these genes in memory CD4  +   T cells 
activated in vitro by TNF-pretreated ECs despite alterations 
in IL-17 production (  Fig. 3 B   and   Fig. 1 F  ). Expression of 
RORC appeared to be increased in T cells co-cultured with 
TNF-pretreated ECs in an IL-1  –  dependent manner; how-
ever, this change did not reach statistical signifi  cance when 
corrected for multiple comparisons. By immunofl  uorescence 
staining, we observed that     10% of the CD3  +   T cells infi  l-
trating the intimas of human artery grafts also express CD161, 
and IL-1 blockade did not alter the proportion of CD3  +   T 
cells that expressed CD161 (  Fig. 3 C  ). These data indicate 
that graft-derived IL-1 promotes allogeneic T cell intimal in-
fi  ltration and directs alloreactive T cells toward IL-17 and 
away from IFN-     production in a model of human artery 
graft rejection in vivo. However, although IL-1 alters the 
cytokines produced by artery-infi  ltrating memory T cells, it 
does not cause obvious alterations in T cell markers associated 
with Th1- or Th17-like subsets. 
  IL-17 induces infl  ammatory responses in human vascular cells 
  Based on rodent studies, IL-17 is proposed to be a mediator 
of acute infl  ammation. To confi  rm this in human tissues, re-
combinant IL-17 was injected intradermally into human skin 
grafts transplanted onto immunodefi  cient mice, and the grafts 
were harvested 6 h later. In this model, healed-in human skin 
grafts transplanted onto CB.17 SCID/beige mice are per-3150 IL-1 IN HUMAN EXPERIMENTAL ALLOGRAFT REJECTION   | Rao et al. 
    DISCUSSION   
  Using models of human T cell responses to allogeneic vascu-
lar cells in vitro and in vivo, we demonstrate important roles 
for graft-derived IL-1 in shaping the host antigraft adaptive 
immune response and in promoting T cell  –  mediated injury 
to allogeneic vasculature. Specifi  cally, we demonstrate that 
the EC lining of human artery segments interposed into the 
consequences, because IL-17 neutralization also reduced the 
transcript levels of CCR6, but not CXCR3, in rejecting 
grafts (  Fig. 6 D  ). These data suggest that T cell production of 
IL-17, enhanced by IL-1, alters the infl  ammatory environ-
ment to further attract additional infl  ammatory CCR6  +   T 
cells, but that IL-17 is not necessary for recruitment of 
CXCR3  +   T cells, a likely source of IFN-    . 
    Figure 3.         IL-1 blockade does not alter memory CD4  +   T cell expression of Th17-associated markers.   (A) RT-PCR analysis of T cell genes 
normalized to CD3     in artery grafts undergoing T cell  –  mediated rejection treated with IL-1Ra or PBS. Means   ±   SEM (  n   = 10 per group) are shown. 
(B) RT-PCR analysis of T cells activated by co-culture with CD32-transduced ECs overlayed with anti-CD3 mAb. ECs pretreated with TNF or left 
untreated were overlayed with anti-CD3 mAb and co-cultured with purified, memory CD4  +   T cells with an anti  –  IL-1     antibody for 3 d. T cells were 
then rested with 3 d and RNA was isolated. Gene expression was normalized to CD3    , and means   ±   SEM of fold changes relative to the untreated, 
isotype control group from six different donors are shown. (C) Immunofluorescence microscopy of intimal T cells stained with anti-CD3 (red) and 
anti-CD161 (green). The arrowhead points to a cell positive for both CD161 and CD3. Quantification of CD161  + /CD3 +   double-positive cells is ex-
pressed as a fraction of total CD3  +   T cells in the intimas of artery grafts treated with IL-1Ra or PBS. Means   ±   SEM (  n   = 7 per group) are shown. 
Bars,  10   μ m.   JEM VOL. 205, December 22, 2008 
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strains (  45  ). Although most studies have focused on diff  eren-
tiation of naive T cells, cytokine production from memory 
CD4  +   T cells can also be modulated by the environment. For 
example, polarized Th1 cells from both humans and mice can 
be induced to produce Th2 cytokines by activation under 
strongly Th2-polarizing conditions and vice versa, although 
this plasticity may be more pronounced in human compared 
with mouse T cells (  46  –  48  ). In addition, we have previously 
shown that addition of exogenous IL-1 to human EC  –  T cell 
co-cultures can selectively skew alloreactive memory CD4  +   
T cells toward IL-17 production (  12  ). We now show that 
human ECs express suffi   cient bioavailable IL-1    , up-regu-
lated either by treatment with exogenous TNF or by TNF 
produced by alloreactive memory CD4  +   T cells, to selec-
tively promote IL-17 production from alloreactive memory 
T cells. The presence of this cell-associated, bioactive IL-1     
suggests that serum levels of IL-1, even when collected from 
a local site, may not accurately predict the activity of this me-
diator in modulating T cell  –  driven pathological processes. 
  Although several cytokines, including IL-1, IL-6, IL-23, 
TGF-    , and IL-21, have been suggested to contribute to the 
development of IL-17  –  producing T cells in vitro (  12, 31  –  35, 
49  ), little information exists on which factors may be relevant 
in human immune responses in vivo (  50  ). Using a human  –
  mouse model of human artery allograft rejection, we provide 
the fi  rst evidence that IL-1 promotes IL-17 production from 
human T cells in vivo. Blockade of IL-1 reduces IL-17 ex-
pression but increases IFN-     expression in rejecting human 
artery allografts, suggesting that IL-1 promotes T cell produc-
tion of IL-17 at the expense of IFN-     in vivo. This change in 
cytokine expression could refl  ect a role for IL-1 in directing 
selective T cell recruitment or T cell diff  erentiation in the 
periphery; however, we did not observe signifi  cant alterations 
in the expression of several genes that are preferentially ex-
pressed by human IL-17  –  producing T cells (CCR6, IL-23R, 
infrarenal aortae of immunodefi   cient CB.17 SCID/beige 
mice expresses IL-1     and that blockade of IL-1 with IL-1Ra 
reduces T cell recruitment to the graft intima. Thus, block-
ade of IL-1 appears to protect allograft arteries from a process 
that resembles acute cell-mediated vascular rejection, some-
times described as   “  intimal arteritis.  ”   
  The use of human materials in our work allows for two 
important advances beyond the insights gained from rodent 
transplant models. First, we focus on alloreactive memory 
cells, which are present in signifi   cant numbers in clinical 
transplant recipients but are typically lacking in rodents. Sec-
ond, we can identify signals that alter human T cell responses 
(e.g., IL-17 production), which can diff  er signifi  cantly from 
those that act in mice. Translational studies using humanized 
mouse models, despite being limited by scarce materials and 
few tools for genetic manipulation, are likely to more accu-
rately predict potentially useful therapies (  43  ). Our study 
contributes several novel observations regarding the interac-
tions of IL-1 and IL-17: (a) IL-1     localized on ECs can selec-
tively enhance IL-17 production from human alloreactive 
memory CD4  +   T cells, especially upon restimulation; (b) al-
lograft-expressed IL-1 promotes IL-17 production from hu-
man T cells in vivo; (c) IL-17 drives infl  ammatory responses 
and infl  ammatory T cell recruitment during T cell  –  mediated 
human allograft rejection in vivo; and (d) the principle vascu-
lar cell target of IL-17 appears to be the SMCs rather than 
ECs, a striking diff  erence from the infl  ammatory responses 
mediated by TNF or IL-1. 
  Although best known as an inducer of acute infl  amma-
tion, IL-1 can also modulate adaptive immune responses. 
Recent studies have demonstrated a critical role for IL-1 in 
inducing Th17 diff  erentiation in human naive T cells (  31, 
33  –  35  ). IL-1 can also participate in the diff  erentiation  of 
mouse Th17 cells (  28, 44  ); however, some eff  ects of IL-1 on 
mouse T cell diff  erentiation appear to diff  er between mouse 
    Figure 4.         IL-17 induces acute infl  ammatory responses in human skin grafts.   Well-healed skin grafts on CB.17 SCID/beige mice were harvested 6 h 
after injection of 1   μ  g IL-17 or PBS. (A) Immunohistochemical quantifi  cation of Gr-1  +   mouse neutrophils in human skin grafts. Bars, 100   μ  m. (B) Quanti-
tative RT-PCR analysis of IL-6 and CCL20 expression normalized to GAPDH in injected grafts. (C) Immunohistochemical identifi  cation of human E-selec-
tin  +   vessels (arrow) in skin grafts. Bars, 25   μ  m. Data are pooled from two independent experiments with similar results, and means   ±   SEM  ( n   = 6 per 
group) are shown in A and B. *, P   <   0.05; #, P   <   0.01.     3152 IL-1 IN HUMAN EXPERIMENTAL ALLOGRAFT REJECTION   | Rao et al. 
This possibility may be particularly relevant for IL-17, which 
can be produced by T cells that also make IFN-     (  25, 26  ). 
Indeed, human IL-17  –  producing and IFN-      –  producing T 
cell clones show signifi  cant overlap in expression of diff  eren-
tiation markers and have been suggested to share a common 
developmental program (  26  ). Nevertheless, the data presented 
in this paper suggest that the eff  ector responses of alloreactive 
and RORC) with IL-1 blockade in artery grafts in vivo or in 
purifi  ed memory CD4  +   T cells activated with ECs expressing 
high levels of IL-1     in vitro. These observations suggest that, 
rather than having an eff  ect on lineage specifi  cation, IL-1 
may alter eff  ector cytokine production in undiff  erentiated or 
partially diff  erentiated human memory T cells, which show 
considerable plasticity in cytokine production phenotypes (  47  ). 
    Figure 5.         IL-17 induces infl  ammatory gene expression in cultured human SMCs.   (A) ECs were treated with 100 ng/ml IL-17 for 6 h, and target gene 
expression was measured by quantitative RT-PCR. Data shown are means   ±   SD of triplicate samples from one of two independent experiments with similar 
results. (B) ECs were treated with 100 ng/ml IL-17, and the culture medium was assayed for IL-6, CXCL8, and CCL20 by ELISA. Means   ±   SEM (  n   = 3 experi-
ments) are shown. (C) Measurement of surface E-selectin and ICAM-1 expression on ECs treated for 6 h with 100 ng/ml IL-17 (dashed line), 10 ng/ml TNF 
(dotted line), or vehicle control (continuous line) by fl  ow cytometry. Shaded histograms represent staining with an isotype-matched control antibody. Repre-
sentative data are from one of three independent experiments with similar results. (D and E) SMCs were treated with 100 ng/ml IL-17 for the indicated 
times (D) or with IL-17 at the indicated concentrations for 6 h (E), and target gene expression was measured by quantitative RT-PCR. (F) SMCs were treated 
with 100 ng/ml IL-17 for 24 h, and the culture medium was assayed for IL-6, CXCL8, and CCL20 by ELISA. (G) SMCs were treated with the IL-17 and TNF 
alone or in combination, and the culture medium was assayed for CCL20 by ELISA. Means   ±   SEM from four (E and G) or six (D and F) experiments are shown.     JEM VOL. 205, December 22, 2008 
ARTICLE
3153
experiments. Alternatively, our inability to detect IL-17F and 
IL-22 may suggest that the IL-17A detected in the artery 
grafts is produced by undiff  erentiated memory T cells or by 
IFN-    /IL-17 double producers rather than bona fi  de Th17 
cells. It is also clear that IL-1 blockade has other protective 
eff  ects beyond modulating T cell cytokine profi  les, such as 
reducing the extent of T cell infi  ltration. 
  Elevated levels of IL-17 have been reported in several 
human autoimmune diseases; however, specifi  c eff  ects of 
human T cell production of IL-17 in vivo have yet to be 
reported. In the model of human artery graft rejection de-
scribed in this paper, neutralization of IL-17 markedly re-
duces expression of certain proinfl  ammatory molecules such 
as IL-6, IL-8, and CCL20 within the graft while leaving ex-
pression of CXCL10, an IFN-      –  inducible chemokine, unaf-
fected. IL-6, CXCL8, and CCL20 are known IL-17 –  inducible 
genes (  27  ); however, the effi   cacy of IL-17 neutralization is 
somewhat surprising given that IL-17 is far less potent at in-
ducing expression of these molecules than IL-1 or TNF (un-
published data). These data indicate that in the absence of 
other human leukocytes, allogeneic T cell  –  mediated induc-
tion of these acutely infl  ammatory transcripts requires the ac-
tion of IL-17. Our fi  nding that IL-17 synergizes with TNF to 
induce CCL20 production by cultured SMCs suggests that 
these factors may act in concert within the vessel wall to drive 
chemokine expression and that interference with one single 
factor can strongly reduce CCL20 production. 
  The reduction in CCL20 expression caused by IL-17 
neutralization appears functional because it is associated with 
a corresponding decrease in CCR6 expression within the 
graft, suggesting that alloreactive T cell  –  derived IL-17 propa-
gates an infl  ammatory cascade that promotes further accumu-
lation of infl  ammatory,  CCR6  +   T cells during human 
allograft rejection. Because our conclusion is based on mRNA 
levels, we cannot distinguish whether this reduction in 
CCR6  +   cells represents a change in the number of CCR4  +  /
CCR6  +   T cells that produce only IL-17 or the number of 
cells in the CCR6  +  /CXCR3  +   population that produce both 
IL-17 and IFN-     (  25  ). Interestingly, IL-1 blockade did not 
memory T cells, in this case production of IL-17, can be mod-
ulated by signals in the microenvironment of the target tissue 
(e.g., by IL-1     expressed on graft endothelium). 
  We also observed that in addition to decreasing IL-17 ex-
pression by artery-infi  ltrating T cells, IL-1 blockade signifi  -
cantly diminished T cell  –  mediated graft injury, as assessed by 
T cell intimal infi  ltration, neointimal expansion, and outward 
arterial remodeling. Our group has previously demonstrated a 
key role for T cell production of IFN-     in promoting arterial 
injury and pathological remodeling in this model (  51, 52  ); 
therefore, it may seem initially surprising that IL-1 blockade 
reduces neointimal expansion without reducing IFN-     ex-
pression by those T cells that do infi  ltrate the vessel wall. The 
likely explanation is that the eff  ect of IL-1 blockade on the 
extent of T cell infi  ltration into the neointima signifi  cantly 
reduces the total amount of IFN-     in the intima. The eff  ect 
on intimal T cell numbers by IL-1 blockade may relate to T 
cell recruitment, T cell retention, or T cell proliferation and 
survival, all of which could be infl  uenced by IL-1. The failure 
to reduce IFN-     by individual T cells in vivo diff  ers from our 
observed eff  ects in vitro, when T cells were co-cultured with 
allogeneic ECs. These diff  erences may relate to an incom-
plete blockade of IL-1 by IL-1Ra in vivo, perhaps because of 
rapid clearance, or may suggest that alloreactive T cells within 
the wall more closely resemble our secondary stimulation of 
T cells in which the eff  ects of IL-1 on IFN-     during the ini-
tial activation are no longer observed. 
  The correlation between reduced intimal infi  ltration and 
reduced IL-17 expression caused by IL-1 blockade suggested 
a potential pathological role for IL-17; however, unlike IL-1 
blockade, IL-17 neutralization failed to reduce T cell intimal 
infi  ltration and neointimal expansion. As IL-1 appears to be 
an upstream inducer of IL-17, it is possible that blockade of 
IL-1 may inhibit production of other Th17-derived cyto-
kines, including IL-17F and IL-22, and may thus be more ef-
fective than blockade of individual Th17 eff  ector cytokines 
in limiting Th17-mediated pathology. We were unable to 
evaluate this possibility because the expression levels of IL-
17F and IL-22 were too low to accurately measure in these 
    Table I.        IL-17  –  induced up-regulation of cytokines and chemokines in SMCs 
Transcript Microarray (fold increase) qPCR (fold increase) Inhibited by cycloheximide
BMP2 4.4/3.9 2.5 Yes
CCL20 5.5 7.7 No
CXCL1 2.2 13.7 No
CXCL3 4.9 7.9 No
IL-1    2.6/2.6 11.1 No
IL-6 2.8 4.4 No
CXCL8 2.5/3.3 17.2 No
IL-11 20.8/3.6 3.7 Yes
LIF 4.1 2.7 No
SMCs were treated with 100 ng/ml IL-17 for 6 h in three independent experiments using different donors. The mean fold change of cytokine and chemokine transcript 
expression in response to IL-17 treatment was assessed by microarray (certain cytokines were represented by more than one probe) and quantitative RT-PCR (qPCR). 
Transcripts for which IL-17  –  mediated up-regulation was not diminished by 10   μ  g/ml cycloheximide, as assessed by RT-PCR, were considered primary gene targets.3154 IL-1 IN HUMAN EXPERIMENTAL ALLOGRAFT REJECTION   | Rao et al. 
ment or development of human neutrophils and DCs will be 
required to further evaluate these eff  ects. 
  The eff  ects of neutralizing IL-17 on overall graft pathol-
ogy are less than those observed by blocking IL-1 and much 
less than those observed by blocking IFN-     (  52  ). Indeed, 
IFN-     still appears to be the central and nonredundant eff  ec-
tor cytokine in our model. Nevertheless, our results suggest 
that IL-1 blockade may be a useful adjunct therapy to prevent 
vascular rejection, an idea supported by results in mouse and 
rat cardiac transplant models showing delayed acute rejection 
cause a similar specifi  c reduction in CCR6 expression in re-
jecting artery grafts, which may suggest that a more complete 
inhibition of IL-17, as achieved with antibody neutralization 
of IL-17 compared with treatment with IL-1Ra, is required 
to aff  ect subsequent CCR6  +   T cell recruitment. IL-17  –  in-
duced production of chemokines that recruit neutrophils 
(CXCL8) and DCs (CCL20) observed in the experiments 
presented in this paper would be expected to contribute to 
the rejection of human allografts; however, more complete 
human  –  mouse chimeric models that allow for the engraft-
    Figure 6.         IL-17 blockade reduces infl  ammatory responses during allogeneic T cell  –  mediated rejection of human artery grafts.   Human  PBMCs 
were adoptively transferred into mice bearing human artery interposition grafts, and mice were treated three times weekly with a neutralizing anti  –  IL-17 
antibody or an isotype control. (A) 5-  μ  m transverse sections were EVG stained, and the vessel area and the intimal area were quantifi  ed using ImageJ 
software. Bars, 100   μ  m. (B) Immunohistochemical identifi  cation and quantifi  cation of human CD45RO  +   T cells in graft intimas. Bars, 25   μ  m. (C) RT-PCR 
analysis of cytokine and chemokine expression (normalized to GAPDH) in grafts from mice treated with an anti  –  IL-17 antibody or an isotype control. 
(D) RT-PCR analysis of chemokine receptor expression (normalized to CD3    ) in grafts from mice treated with an anti  –  IL-17 antibody or an isotype control. 
Means   ±   SEM are shown (IgG,   n   =  6;  anti – IL-17,   n   = 5). *, P   <   0.05; #, P   <   0.01.     JEM VOL. 205, December 22, 2008 
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fresh ECs from the same donor as used in the primary co-culture. For poly-
clonal restimulation assays, ECs transduced with a retrovirus encoding CD32, 
as previously described, were pretreated with TNF and overlayed with 1   μ  g/ml 
anti-CD3 for 30 min before co-culture with purifi  ed memory CD4  +   T 
cells (  38  ). After 3 d of co-culture, T cells were rested for 3 d with 10 U/ml 
IL-2 and restimulated with 10 ng/ml PMA and 1   μ  M ionomycin (Sigma-
Aldrich) for 5 h in the presence of 10   μ  g/ml brefeldin A (Invitrogen), and were 
analyzed by ICS. T cells were restimulated with PMA and ionomycin. For 
extended primary co-cultures, purifi  ed memory CD4  +   T cells were labeled 
with 250 nM CFSE (Invitrogen) and were added to microtiter plates contain-
ing allogeneic ECs at a T cell/EC ratio of 3:1. 48  –  72 replicate wells were 
plated in each experiment, and a neutralizing antibody to IL-1     (5   μ  g/ml) 
was added to half of the wells. Co-cultures were incubated for 14 d with 
10 U/ml IL-2 added on days 3, 7, and 10. On day 14, co-cultures were restimu-
lated with PMA and ionomycin, as described, and were analyzed by ICS. 
  Arterial transplantation.     All experimental animal protocols were ap-
proved by the Yale University Institutional Animal Care and Use Commit-
tee. Arterial transplantation was performed as previously described (  52  ). In 
brief, 1  –  3-mm segments of human epicardial coronary arteries from ex-
planted hearts of cadaveric organ donors or cardiac transplant recipients were 
interposed into the infrarenal aortae of female SCID/beige mice (Taconic) 
using an end-to-end microsurgical anastomotic technique. Adjacent human 
artery segments were transplanted in groups of two to fi  ve mice for each ex-
periment, and data from individual experiments were pooled to generate 
suffi   cient numbers for analysis. 
  Where indicated in the fi  gures, 3   ×   10  8   human PBMCs allogeneic to the 
artery graft were adoptively transferred into mice intraperitoneally 2  –  7 d after 
artery transplantation. Based on a pilot experiment, we have found that vary-
ing the day of transfer within the fi  rst week after transplant does not signifi  -
cantly aff  ect the rejection response. Successful engraftment, achieved in all 
mice in this study, was defi  ned as detection by fl  ow cytometry of a distinct 
population of human CD3  +   cells, typically ranging from 0.5  –  10% of the total 
mononuclear cell population, in the circulation of mice 7  –  14 d after inocula-
tion. For IL-1 blockade, mice with artery grafts were injected daily subcuta-
neously with 50 or 150 mg/kg IL-1Ra (Amgen) or with PBS as a control 
starting on the day before PBMC transfer. For IL-17 neutralization, animals 
were injected intraperitoneally with a neutralizing mouse anti  –  human IL-17 
antibody (clone 41809; R  &  D Systems) or an irrelevant IgG2b antibody (clone 
20116; R  &  D Systems), starting with a 250-  μ  g loading dose the day before 
PBMC transfer and then a subsequent dose of 125   μ  g three times per week. 
  To harvest transplanted arterial grafts, animals were anesthetized and ar-
terial grafts were perfused with normal saline and excised before death. Arte-
rial grafts were frozen in optimum cutting temperature (OCT) compound, 
and serial 5-  μ  m transverse sections were cut for morphometric, immunohis-
tochemical, and RNA analyses. The graft from one mouse treated daily with 
PBS for 21 d was excluded from analyses because an intravascular thrombus 
was discovered upon graft harvest, and the graft displayed abnormal mor-
phology with no demonstrable T cell infi  ltration or signs of rejection. 
  Skin grafting.     Two human split thickness skin grafts     1 cm  2   in area were 
orthotopically transplanted onto the dorsum of CB.17 SCID/beige mice, as 
previously described (  59  ). Grafts were allowed to heal for 6 wk, and only 
similarly sized, well-healed grafts were used for experiments. Skin grafts 
were injected intradermally with 20   μ  l PBS alone or PBS containing 1   μ  g of 
recombinant human IL-17, and were harvested 6 h later. Skin grafts were 
embedded in OCT, and serial 8-  μ  m sections were cut for immunohisto-
chemical and RNA analyses. 
  Histology and immunohistochemistry.     Microscopic morphometric 
evaluation was performed on Elastica  –  van Gieson (EVG)  –  stained 5-  μ  m cross 
sections of artery grafts using ImageJ software (available at http://rsbweb
.nih.gov/ij/). Serial sections were stained with mouse mAbs against CD31 
(Dako) or IL-1     (R  &  D Systems) using the avidin  –  biotin  –  peroxidase staining 
method (Vector Laboratories). Graft-infi  ltrating human lymphocytes were 
quantifi  ed by staining for human CD45RO (BD) or human CD3 (Dako). 
with IL-1 blockade (  53, 54  ). As IL-1 is well known to be 
produced as a consequence of ischemia-reperfusion injury 
(  55  –  57  ), we propose that IL-1 produced in the periphery as a 
consequence of perioperative injury promotes T cell  –  medi-
ated infl   ammation locally within an allograft and further 
modulates the nature of the T cell response. Perioperative 
blockade of IL-1 thus represents an attractive new therapeu-
tic strategy in clinical transplantation that will need to be 
tested experimentally. This role of IL-1 on T cell responses 
may also carry signifi  cant implications for autoimmunity, tu-
mor immunotherapy, and stroke. 
  MATERIALS AND METHODS 
  Isolation and culture of human cells.     All human cells and tissues, includ-
ing skin and blood vessels, were obtained and used under protocols approved 
by the Institutional Review Groups of Yale University and the New Eng-
land Organ Bank. CD4  +   T cells were isolated from human PBMCs by posi-
tive selection using CD4 Dynabead (Invitrogen) magnetic bead separation 
and were released from the beads with DETACHaBEAD (Invitrogen), as 
previously described (  12  ). Activated T cells and monocytes were routinely 
depleted from CD4-selected populations by further negative selection using 
a mouse anti  –  human HLA-DR antibody (clone LB3.1; a gift from J. 
Strominger, Harvard University, Cambridge, MA). Memory CD4  +   T cells 
were isolated from CD4-selected populations by negative selection using 
anti-CD45RA antibody (eBioscience), followed by incubation with goat 
anti  –  mouse antibody  –  coated beads (Invitrogen). 
  Human umbilical vein ECs were isolated from umbilical cords and cul-
tured as previously described (  58  ). Such cultures are uniformly positive for 
von Willebrand factor and CD31, and lack detectable contamination by 
CD45-expressing leukocytes. In some experiments, MHC class II expression 
lost during culture was restored by retroviral transduction with class II trans-
activator, as previously described (  38  ). In brief, ECs were washed with 
HBSS, overlayed with virus-containing medium for 4  –  6 h, and returned to 
complete media overnight. MHC class II expression was confi  rmed by fl  ow 
cytometry, and four to fi  ve rounds of transduction routinely achieved   >  85% 
transduction effi   ciency. 
  Human aortic or coronary artery SMCs were isolated by explant out-
growth and serially cultured. No phenotypic diff  erences were detected be-
tween the two types of SMCs, and cells were used at passages three to four. 
For quantitative RT-PCR and ELISA analyses, cells were serum deprived in 
0.5% PBS for 48 h before treatment with cytokines. For microarray analyses, 
SMCs were maintained in 20% FBS-supplemented medium and treated 
with or without 100 ng/ml IL-17 (R  &  D Systems) for 6 h. 
  To measure changes in IL-1     in ECs after co-culture with T cells, class 
II transactivator  –  transduced ECs were co-cultured with allogeneic CD4  +   T 
cells for 3 d, and adherent cells were collected with trypsin and depleted of 
contaminating T cells by negative depletion using anti-CD4  +   beads (Invitro-
gen). In experiments comparing changes in IL-1     expression in ECs and 
SMCs after co-culture with T cells, MHC class II expression was induced in 
both ECs and SMCs by pretreatment with 50 ng/ml IFN-     for 3 d before 
co-culture. ECs or SMCs after co-culture or cytokine treatment were lysed 
in 50 mM Tris (pH 7.4), 300 mM NaCl, 10% glycerol, 3 mM EDTA, 1 mM 
MgCl  2  , 20 mM     -glycerophosphate, 25 mM NaF, 1% Triton X-100, 25 
  μ  g/ml leupeptin, 25   μ  g/ml pepstatin, and 3   μ  g/ml aprotinin, and lysates 
normalized to a concentration of 1 mg/ml were analyzed by ELISA. 
  T cell activation in vitro  .       Class II transactivator  –  transduced ECs were 
pretreated with 10 ng/ml TNF (R  &  D Systems), as indicated in the fi  gures, 
and were washed three times with HBSS to remove TNF. Purifi  ed memory 
CD4  +   T cells were added at a density of 1  –  2   ×   10  6   cells/ml in RPMI 1640 
supplemented with 10% FBS, 2 mM   l-  glutamine, and 100 U/ml penicillin, 
and 100   μ  g/ml streptomycin (Invitrogen). For allogeneic restimulation assays, 
memory CD4  +   T cells were co-cultured with allogeneic, MHC class II  –  posi-
tive ECs for 3 d, rested for 3 d with 10 U/ml IL-2, and restimulated with 3156 IL-1 IN HUMAN EXPERIMENTAL ALLOGRAFT REJECTION   | Rao et al. 
transformed values to allow for a normal distribution of the data. P   <   0.05 
was considered signifi  cant. 
  Online supplemental material.     The online supplemental fi  gures provide 
information on the diff  erential ability of human allogeneic CD4  +   T cells 
to induce IL-1     expression in human ECs and SMCs (Fig. S1), and the 
lack of eff  ect of IL-1Ra and anti  –  IL-17A mAb on the adoptive transfer 
of human T cells into immunodefi  cient SCID/beige mice (Fig. S2). Table S1 
lists all of the genes up- or down-regulated more than twofold by IL-17 
in human smooth muscles, as detected by the Aff  ymetrix  microarray 
analysis. Online supplemental material is available at http://www.jem
.org/cgi/content/full/jem.20081661/DC1. 
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